利妥昔单抗注射液联合化疗治疗B细胞非霍奇金淋巴瘤的效果观察  

Observation of effect by rituximab injection combined with chemotherapy in the treatment of B cell non-hodgkins lymphoma non-hodgkin's lymphom

作　　者：鲁一[1] 

机构地区：[1]新乡市中心医院肿瘤内科,453000

出　　处：《中国实用医药》2015年第34期13-14,共2页China Practical Medicine

摘　　要：目的研究B细胞非霍奇金淋巴瘤运用利妥昔单抗注射液联合化疗治疗的临床效果。方法 128例B细胞非霍奇金淋巴瘤患者,将其随机分为对照组和观察组,各64例。对照组患者采用单纯性CHOP方案进行化疗,观察组患者采用利妥昔单抗注射液联合化疗的方法进行治疗,比较两组患者的临床治疗效果。结果观察组总有效率90.63%高于对照组71.88%,差异有统计学意义(P<0.05);两组患者治疗过程中出现不良反应的情况比较,差异无统计学意义(P>0.05)。结论对B细胞非霍奇金淋巴瘤实施治疗时,选择利妥昔单抗注射液联合化疗治疗的临床效果显著,同时患者具有很好的耐受性,毒副作用不明显,适合在临床上推广使用。Objective To research clinical effect by rituximab injection combined with chemotherapy in the treatment of B cell non-hodgkin＇s lymphoma. Methods A total of 128 patients with B cell non-hodgkin＇s lymphoma were randomly divided into control group and observation group, with 64 cases in each group. The control group received single CHOP regimen for chemotherapy, and the observation group received rituximab injection combined with chemotherapy for treatment. Clinical effects of the two groups were compared. Results The observation group had higher total effective rate as 90.63% than 71.88% of the control group, and their difference had statistical significance（P〈0.05）. The difference of adverse reactions during treatment had no statistical significance between the two groups（P〉0.05）. Conclusion Implement of rituximab injection combined with chemotherapy provides precise clinical effect in the treatment of B cell non-hodgkin＇s lymphoma. This method contains good compliance and slight adverse reactions, and it is worthy of clinical promotion and application.

关 键 词：利妥昔单抗注射液 化疗 B细胞非霍奇金淋巴瘤 临床效果 

分 类 号：R733.1[医药卫生—肿瘤]